Trials / Conditions / Membranoproliferative Glomerulonephritis

Membranoproliferative Glomerulonephritis

12 registered clinical trials studyying Membranoproliferative Glomerulonephritis — 3 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Developing a Pipeline to Employ RNA-Seq as a Complementary Diagnostic Tool in Rare Diseases NCT05996731	Mario Negri Institute for Pharmacological Research	N/A
Active Not Recruiting	New Analytic Tools for aHUS and C3G Diagnosis NCT05985122	Mario Negri Institute for Pharmacological Research	N/A
Active Not Recruiting	An Open-Label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of Peg NCT05809531	Apellis Pharmaceuticals, Inc.	Phase 3
Completed	Phase III Study Assessing the Efficacy and Safety of Pegcetacoplan in Patients With C3 Glomerulopathy or Immun NCT05067127	Apellis Pharmaceuticals, Inc.	Phase 3
Active Not Recruiting	Study Assessing the Safety and Efficacy of Pegcetacoplan in Post-Transplant Recurrence of C3G or IC-MPGN NCT04572854	Apellis Pharmaceuticals, Inc.	Phase 2
Recruiting	Evaluation of a Renin Inhibitor, Aliskiren, Compared to Enalapril, in C3 Glomerulopathy NCT04183101	Region Skane	Phase 2
Completed	Daratumumab in Treatment of PGNMID and C3 GN NCT03095118	Fernando Fervenza	Phase 2
Unknown	Effect of Rituximab in Treatment of Membranoproliferative Glomerulonephritis NCT03180723	Assiut University	Phase 3
Completed	Eculizumab in Primary MPGN NCT02093533	Mario Negri Institute for Pharmacological Research	Phase 2
Completed	Eculizumab Therapy for Dense Deposit Disease and C3 Nephropathy NCT01221181	Columbia University	Phase 1
Recruiting	National Registry of Rare Kidney Diseases NCT06065852	UK Kidney Association	—
Approved For Marketing	C3G/Primary IC-MPGN EAP NCT04729062	Apellis Pharmaceuticals, Inc.	—